Get the latest Science News and Discoveries
Study: Access to targeted lung cancer drug is cost-prohibitive globally - EurekAlert
A new study from Sylvester Comprehensive Cancer Center examined the cost-effectiveness of durvalumab, a targeted immunotherapy for lung cancer that is known to extend lifespan. The study could help guide drug-pricing strategies to reduce financial burdens and increase the number of patients who benefit from treatment.
None
Or read this on Eureka Alert